ABVX
Abivax S.A.·Healthcare
126.14
0.358%(+0.45)
Market ClosedLast Updated: — ET
52W L: $5.5952W H: $148.83
ABVX NEWS
fool.com
3d ago
This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?
Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.
globenewswire.com
Apr 1
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 23, 2026. The Universal Registration Document includes the 2025 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
seekingalpha.com
Apr 1
Abivax: Obefazimod's Strategic Scarcity Drives Optionality (Maintaining Buy)
Abivax remains a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohn's disease. Updated phase 3 and UEG safety data further de-risk ABVX, supporting earlier line use and expanding market potential beyond refractory patients. I raise my probability of success to 95%, increasing the 12-month target price to $140 per share, reflecting ~25% upside.
fool.com
Mar 26
2 Healthcare Stocks That Could Soar Over the Next 5 Years
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
benzinga.com
Mar 24
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
• Abivax stock is taking a hit today. Why is ABVX stock falling?
cnbc.com
Mar 24
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French biotech company for months, with analysts seeing it as a prime takeover target.
